Correlation between PAMPA permeability and cellular activities of hepatitis C virus protease inhibitors.

Parallel artificial membrane permeability assay (PAMPA) and Caco-2 cells have been frequently used for the evaluation of in vitro permeability of new chemical entities. In this study we evaluated the correlation between permeability, assessed by both methods, and the cellular potency of 34 novel hepatitis C virus (HCV) protease inhibitors. Two types of assays were used to determine the potency of HCV protease inhibitors: a cell-free assay that evaluates the intrinsic affinity (K(i)) between the protease and the inhibitor and a cell-based replicon assay that determines the inhibitors' IC90. When the K(i)/IC90 ratios were compared with the PAMPA permeability and the Caco-2 permeability by linear regression analysis, a reasonable correlation was found between the K(i)/IC90 ratio and PAMPA permeability (r2=0.76) but not with Caco-2 permeability (r2=0.29). Correlations were also assessed between K(i)/IC90 ratios and the following physico-chemical properties: logP (r2=0.41), logD (r2=0.58), clogP (r2=0.13), and mlogP (r2=0.30). These results suggest that passive permeability may play a role in the uptake and cellular activity of these HCV protease inhibitors, and that PAMPA was more predictive of cellular activity than physico-chemical properties or Caco-2 permeability.

[1]  Steven R. LaPlante,et al.  An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus , 2003, Nature.

[2]  Li Di,et al.  PAMPA--critical factors for better predictions of absorption. , 2007, Journal of pharmaceutical sciences.

[3]  S. Tamura,et al.  Discovery of SCH446211 (SCH6): a new ketoamide inhibitor of the HCV NS3 serine protease and HCV subgenomic RNA replication. , 2006, Journal of medicinal chemistry.

[4]  Alex Avdeef,et al.  Absorption and drug development , 2003 .

[5]  L. Benet,et al.  Effects of Uptake and Efflux Transporter Inhibition on Erythromycin Breath Test Results , 2007, Clinical pharmacology and therapeutics.

[6]  M. Strafford,et al.  Drug absorption in vitro model: filter-immobilized artificial membranes. 2. Studies of the permeability properties of lactones in Piper methysticum Forst. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[7]  R. Borchardt,et al.  How structural features influence the biomembrane permeability of peptides. , 1996, Journal of pharmaceutical sciences.

[8]  Richard A. Morrison,et al.  Evaluation of Biocoat® Intestinal Epithelium Differentiation Environment (3-Day Cultured Caco-2 Cells) as an Absorption Screening Model with Improved Productivity , 1997, Pharmaceutical Research.

[9]  P. Carrupt,et al.  Parallel artificial membrane permeability assay: a new membrane for the fast prediction of passive human skin permeability. , 2006, Journal of medicinal chemistry.

[10]  Walter A. Korfmacher,et al.  Lead Optimization in Discovery Drug Metabolism and Pharmacokinetics/Case study: The Hepatitis C Virus (HCV) Protease Inhibitor SCH 503034 , 2007, Perspectives in medicinal chemistry.

[11]  L. Benet,et al.  Effect of OATP1B Transporter Inhibition on the Pharmacokinetics of Atorvastatin in Healthy Volunteers , 2007, Clinical pharmacology and therapeutics.

[12]  Weiying Yang,et al.  Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: , 2006, Journal of medicinal chemistry.

[13]  S. Chong,et al.  In Vitro Permeability Through Caco-2 Cells is not Quantitatively Predictive of in Vivo Absorption for Peptide-Like Drugs Absorbed via the Dipeptide Transporter System , 2004, Pharmaceutical Research.

[14]  J. Schellens,et al.  Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs. , 2006, Trends in pharmacological sciences.

[15]  M. Másson,et al.  Development and evaluation of an artificial membrane for determination of drug availability. , 2006, International journal of pharmaceutics.

[16]  R. Borchardt,et al.  The Effect of β-Turn Structure on the Passive Diffusion of Peptides Across Caco-2 Cell Monolayers , 1997, Pharmaceutical Research.

[17]  Yuichi Sugiyama,et al.  Comparative Studies on in Vitro Methods for Evaluating in Vivo Function of MDR1 P-Glycoprotein , 2001, Pharmaceutical Research.

[18]  M. Kansy,et al.  Permeation of permanently positive charged molecules through artificial membranes--influence of physico-chemical properties. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[19]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[20]  The Effect of Conformation on Membrane Permeability of an Acyloxyalkoxy-linked Cyclic Prodrug of a Model Hexapeptide , 1996, Pharmaceutical Research.

[21]  W. Rubas,et al.  Comparison of the Permeability Characteristics of a Human Colonic Epithelial (Caco-2) Cell Line to Colon of Rabbit, Monkey, and Dog Intestine and Human Drug Absorption , 2004, Pharmaceutical Research.

[22]  Chuang Lu,et al.  Comparison of Intrinsic Clearance in Liver Microsomes and Hepatocytes from Rats and Humans: Evaluation of Free Fraction and Uptake in Hepatocytes , 2006, Drug Metabolism and Disposition.

[23]  P. Artursson.  Cell cultures as models for drug absorption across the intestinal mucosa. , 1991, Critical reviews in therapeutic drug carrier systems.

[24]  Leann Nguyen,et al.  Is PAMPA a useful tool for discovery? , 2007, Journal of pharmaceutical sciences.

[25]  C. Rice,et al.  Overview of hepatitis C virus genome structure, polyprotein processing, and protein properties. , 2000, Current topics in microbiology and immunology.

[26]  R A Morrison,et al.  Current methodologies used for evaluation of intestinal permeability and absorption. , 2000, Journal of pharmacological and toxicological methods.

[27]  V. Pazienza,et al.  In vitro antiviral activity of SCH446211 (SCH6), a novel inhibitor of the hepatitis C virus NS3 serine protease. , 2006, The Journal of antimicrobial chemotherapy.